| Trial ID # | NCT03596281; PEMBOV |
| Phase | I |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Liposomal doxorubicin, Pembrolizumab, Bevacizumab |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | Bev+Pem: 19 patients, Bev+PLD+Pem: 22 patients, median 3 prior therapies (1-13), 41% primary Pt-R, 82% w/ prior Bev, 41% w/ prior PARPi |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | CBR, ORR, DCR, PFS, evaluated per RECIST |
| Efficacy | Bev+Pem: Bev+PLD+Pem: |
| Conclusion | Pembrolizumab+bevacizumab with or without liposomal doxorubicin is well tolerated and demonstrate durable responses in platinum resistant ovarian cancer patients |
| Reference | Michels J et al. Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients. SITC (2021) abstract 355 Michels J et al. PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer. J Clin Oncol 40, 2022 (suppl 16; abstr 5575) Michels J et al. Poster |